Inquire About a Product| Product: | Fulvestrant-d3 | ||||
|---|---|---|---|---|---|
| Catalog Number: | D3621 | ||||
| Unlabeled CAS Number: | 129453-61-8 | ||||
| Synonyms: |
(7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl], (7α, 17β)-estra-1,3,5(10)-triene-3,17-diol-d3; Faslodex-D3 |
||||
| Pricing: |
|
||||
| Formula: | C32H44F5O3SD3 | ||||
| Enrichment: | 98%D | ||||
| Molecular Weight: | 609.79 | ||||
| Structure: |
|
||||
| Category: | Labeled Steroids & Hormones | ||||
| Literature References: |
Scott SM, Brown M, Come SE, Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer. Expert Opin Drug Saf, 2011, 10 (5): 819–26.; Croxtall JD, McKeage K., Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. Drugs, 2011, 71 (3): 363–80. |
||||
| MSDS: | |||||
| Applications: | A labeled estrogen receptor antagonist with no agonist effects. Used as a treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. A selective estrogen receptor down-regulator. |